These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W, Chaney SG. Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361 [Abstract] [Full Text] [Related]
5. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N, Lam YM, Pym J, Campling BG. Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677 [Abstract] [Full Text] [Related]
6. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cancer Res; 1993 Nov 01; 53(21):5225-32. PubMed ID: 8106143 [Abstract] [Full Text] [Related]
9. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477 [Abstract] [Full Text] [Related]
10. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas. Rose WC, Basler GA. In Vivo; 1990 Dec 15; 4(6):391-6. PubMed ID: 2103379 [Abstract] [Full Text] [Related]
13. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF, Koberle B, Masters JR, Kelland LR. Br J Cancer; 1999 Dec 15; 81(8):1294-303. PubMed ID: 10604725 [Abstract] [Full Text] [Related]
14. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Hill BT, Shellard SA, Hosking LK, Dempke WC, Fichtinger-Schepman AM, Tone T, Scanlon KJ, Whelan RD. Cancer Res; 1992 Jun 01; 52(11):3110-8. PubMed ID: 1591724 [Abstract] [Full Text] [Related]
15. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Han I, Ling YH, al-Baker S, Khokhar AR, Perez-Soler R. Cancer Res; 1993 Oct 15; 53(20):4913-9. PubMed ID: 8402681 [Abstract] [Full Text] [Related]
16. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Cancer Res; 1988 Oct 15; 48(20):5713-6. PubMed ID: 3139281 [Abstract] [Full Text] [Related]
17. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines. Tayyem H, Huq F, Yu JQ, Beale P, Fisher K. ChemMedChem; 2008 Jan 15; 3(1):145-51. PubMed ID: 17963210 [Abstract] [Full Text] [Related]
18. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR. Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660 [Abstract] [Full Text] [Related]